New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:09 EDTEGRXEagle Pharmaceuticals' licensor granted U.S. patent for dantrolene
Eagle Pharmaceuticals announced that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension. This patent issued expires in 2023. Eagle’s dantrolene formulation for the treatment of Exertional Heat Stroke was granted Orphan Drug designation by the Food and Drug Administration on September 25, 2012. Eagle is currently developing dantrolene in this new EHS indication. The company filed an NDA in January 2014 for Ryanodex in the treatment of Malignant Hyperthermia which was granted a priority review and has a PDUFA date of July 22, 2014. Ryanodex for the treatment of MH has also received Orphan Drug designation.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:00 EDTEGRXEagle Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information
March 18, 2015
10:08 EDTEGRXEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.
March 17, 2015
09:02 EDTEGRXEagle Pharmaceuticals 1.32M share Spot Secondary priced at $42.00
Subscribe for More Information
March 16, 2015
16:02 EDTEGRXEagle Pharmaceuticals files to sell $50M in common stock
Subscribe for More Information
08:44 EDTEGRXFDA warning on liquid bendamustine may help Eagle's EP-3102, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use